MedPath

Post-Market Clinical Follow-up Performance and Safety Study of Etermis 3 and 4 in the Face

Completed
Conditions
Facial Volume Enhancement
Correction of Facial Wrinkles/Folds
Registration Number
NCT04210258
Lead Sponsor
Merz Pharmaceuticals GmbH
Brief Summary

To confirm the clinical performance of Etermis 3 and Etermis 4 based on the blinded investigator´s assessments on the respective Merz Aesthetics Scales from day 0 (D0) pre-injection to month 6/7 (depending on touch up) visit for nasolabial folds and marionette lines and from D0 pre-injection to month 3/4 (depending on touch up) visit for upper and lower lip fullness.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
154
Inclusion Criteria
  • Subjects seeking hyaluronic acid dermal filler treatment to redefine/volumize/correct at least two of the indicated facial areas:

    • Nasolabial folds
    • Marionette lines
    • Upper and lower lip fullness
Read More
Exclusion Criteria
  • Subjects that have already been injected with non-resorbable filler, or that have recently been treated with any dermal filler in the region to be treated in the study
  • Subjects with known sensitivity to hyaluronic acid-based products
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Responder rate for NLFs after treatment with Etermis 4 based on the blinded Investigator's opinion on the Merz Aesthetics Scale "Nasolabial folds- At Rest"Baseline to month 6-7
Responder rate for marionette lines after treatment with Etermis 4 based on the blinded Investigator's opinion on the Merz Aesthetics Scale "Marionette lines- At Rest"Baseline to month 6-7
Responder rate for lips after treatment with Etermis 4 based on the blinded Investigator's opinion on the Merz Aesthetics Scale "Upper and lower lip fullness - At Rest"Baseline to month 3-4
Responder rate for marionette lines after treatment with Etermis 3 based on the blinded Investigator's opinion on the Merz Aesthetics Scale "Marionette lines- At Rest"Baseline to month 6-7
Responder rate for lips after treatment with Etermis 3 based on the blinded Investigator's opinion on the Merz Aesthetics Scale "Upper and lower lip fullness - At Rest"Baseline to month 3-4
Secondary Outcome Measures
NameTimeMethod
Change of blinded Investigator's assessment of lip volume, per product from D0 pre-injection to M1 visit (before touch-up), to M2, to M3/M4, to M6/M7, to M9/M10, and to M12/M13 according to Merz Aesthetics Scale "Upper and Lower lip fullness - At Rest"Baseline up to month 12-13
Change of blinded Investigator's assessment of nasolabial folds, per product from D0 pre-injection to M1 visit (before touch-up), to M2, to M3/M4, to M6/M7, to M9/M10, and to M12/M13 according to the Merz Aesthetics Scale "Nasolabial folds - At Rest"Baseline up to month 12-13
Blinded Investigator's global opinion on clinical performance on the global aesthetic improvement scale (GAIS) from D0 pre-injection photos to M1 visit pre-optional touch-ups, M2 visit if applicable, M3/M4, M6/M7 visit, M9/M10 visit and to M12/M13 visit.Baseline up to month 12-13
Change of blinded Investigator's assessment of marionette lines, per product from D0 pre-injection to M1 visit (before touch-up), to M2, to M3/M4, to M6/M7, to M9/M10, and to M12/M13 according to the Merz Aesthetics Scale "Marionette lines - At RestBaseline up to month 12-13
Subject's satisfaction on the global impression of changes scale (GICS) from D0 pre-injection photos to M1 visit pre-optional touch-ups, M2 visit if applicable, M3/M4, M6/M7 visit, M9/M10 visit and to M12/M13 visit.Baseline up to month 12-13

Trial Locations

Locations (6)

Merz Investigational Site #0490099

🇩🇪

Darmstadt, Germany

Merz Investigational Site #0490095

🇩🇪

Hamburg, Germany

Merz Investigational Site #0490345

🇩🇪

Hamburg, Germany

Merz Investigational Site #0490368

🇩🇪

München, Germany

Merz Investigational Site #0490362

🇩🇪

Potsdam, Germany

Merz Investigational Site #0490309

🇩🇪

Kassel, Germany

© Copyright 2025. All Rights Reserved by MedPath